Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:HEB
Previous SymbolNYSE:HEB
CUSIPN/A
Phone+1-407-2718516
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees25
Outstanding Shares48,190,000
Market Cap$0.00
OptionableNot Optionable
Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) posted its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $0.09 million during the quarter. View Hemispherx BioPharma's Earnings History.
When is Hemispherx BioPharma's next earnings date?
Has Hemispherx BioPharma been receiving favorable news coverage?
Media coverage about HEB stock has trended neutral on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hemispherx BioPharma earned a news impact score of 0.5 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future.
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 445,720 shares, an increase of 12.5% from the September 28th total of 396,275 shares. Based on an average trading volume of 246,395 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.0% of the company's stock are short sold. View Hemispherx BioPharma's Current Options Chain.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 65)
- Mr. Adam Pascale, CFO & Chief Accounting Officer (Age 70)
- Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 67)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 47)
- Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 72)
How do I buy shares of Hemispherx BioPharma?
Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
One share of HEB stock can currently be purchased for approximately $0.20.
What is Hemispherx BioPharma's official website?
How can I contact Hemispherx BioPharma?
Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.
MarketBeat Community Rating for Hemispherx BioPharma (NYSEAMERICAN HEB)
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
